Trials / Conditions / Refractory High Risk Myelodysplastic Syndrome
Refractory High Risk Myelodysplastic Syndrome
6 registered clinical trials studyying Refractory High Risk Myelodysplastic Syndrome — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re NCT04047641 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomo NCT03896269 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome NCT03359460 | University of California, Davis | Phase 1 |
| Completed | Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leu NCT02649764 | M.D. Anderson Cancer Center | Phase 1 |